TO THE EDITOR
In acute myeloblastic leukemia (AML), cytogenetic abnormalities are one of the most important factors predicting the clinical outcome. However, more than 40% of patients with de novo AML have a normal karyotype, and therefore lack informative cytogenetic markers. The intermediate or adverse cytogenetic risk group includes a heterogeneous cohort of patients, and little is known about the underlying molecular mechanisms contributing to the clinical heterogeneity. To date, several molecular abnormalities have been examined for their clinical significance in AML. For example, internal tandem duplications (ITDs) in the receptor tyrosine kinase FLT3 gene, which are observed in approximately 20% of AML, are associated with an unfavorable clinical outcome. On the other hand, mutations in the transcription factor C/EBPa were seen in about 10% of AML patients and are associated with a favorable clinical outcome. Intriguingly, mutations of these genes were frequently seen in patients with a normal karyotype. Since a considerable number of patients with AML do not have these genetic abnormalities, it is of importance to clarify the clinical significance of further molecular alterations.
Hypermethylation of the p15 gene has been demonstrated in more than 60% of patients with AML, while alteration of the p16 gene and homozygous deletion of the p15 gene were rarely observed.
1-3 However, only a few studies have reported the relationship between p15 methylation and clinical outcome in AML. A trend toward shorter survival was observed among the relatively small numbers of patients with adult AML in whom the p15 gene was methylated. 3 In AML M3, p15 methylation and no p15 mRNA expression correlated with shorter diseasefree survival (DFS). 4 The clinical significance of p15 inactivation largely remains to be determined, although frequent hypermethylation of the p15 gene was selectively observed in AML.
In addition, most analyses of CpG island hypermethylation of the p15 gene employ techniques capable of studying only a few CpG sites within the CpG island, such as Southern blotting analysis using methylation-sensitive restriction enzymes or methylation-specific polymerase chain reaction (PCR). Recent studies of p15 methylation using bisulfite genomic sequencing of whole CpG sites have revealed the pronounced heterogeneity of p15 methylation between individual alleles. The methylation density of the p15 CpG island was correlated with mRNA expression, as analyzed by reverse transcriptase-PCR (RT-PCR).
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Since RT-PCR is not a quantitative method, we thought that a more quantitative analysis of expression was needed to evaluate the silencing of the p15 gene caused by various degrees of methylation. In this study, we established real-time quantitative RT-PCR (RQ-PCR) and examined whether the level of p15 mRNA expression is associated with clinical outcome in AML patients.
We examined bone marrow mononuclear cells (BMMCs) from 108 Japanese patients with de novo AML. BMMCs from 10 patients with malignant lymphoma lacking BM involvement were also examined. Each patient gave informed consent for use of their samples according to guidelines based on the tenets of the revised Helsinki Protocol by the Institutional Committees for the Protection of Human Subjects and Analysis of the Human Genome. Patients were treated with intensive chemotherapy based on the Japan Adult Leukemia Study Group multicenter protocols in the AML87, AML89, AML92 and AML95 studies. For the p15 standard plasmid, 451 bp fragments were amplified using primers spanning exons 1 and 2 of the p15 gene to avoid amplification of genomic sequences. For the GAPDH standard plasmid, primers were designed to amplify 545 bp fragments of the GAPDH gene from the sequences of different exons. The sequences of primers were as follows: p15WS5, 5
0 -TGGGGGCGGCAGCGATGAG-3 0 (357-375) and p15WAS5, 5 0 -AGGTGGGTGGGGGTGGGAAAT-3 0 (807-787) for p15, and gapLS, 5 0 -GGAGCCAAAAGGGTCATCATCT-3 0 (418-439) and gapLA, 5 0 -TCAAAGGTGGAGGAGTGGGTGT-3 0 (962-941) for GAPDH, where the numbers in the parentheses were based on published sequences available from GenBank under Accession Nos. L36844 (p15) and NM_002046 (GAPDH). The PCR products were subcloned into the plasmid pGEM-T Easy Vector (Promega, Madison, WI, USA). Molecular concentrations were calculated and serial dilutions of the standard plasmid were prepared. We designed primers and the TaqMan probe for p15 RQ-PCR, which produced 169 bp PCR fragments spanning exons 1 and 2, to avoid amplification of p16 mRNA whose exon 2 is highly homologous to the p15 gene. We also designed primers and a probe for GAPDH RQ-PCR, which amplified 101 bp PCR fragments, using the Primer-Express Software (Applied Biosystems, Foster City, CA, USA). The sequences of primers and probes for RQ-PCR were as follows: p15WS3, (576-603) for GAPDH. To correct for differences in the RNA quantity, we calculated the ratio of the copy numbers of p15 and GAPDH mRNA transcripts in a given sample. Amplification and data analysis were carried out using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). All samples were examined in duplicate. Bisulfite genomic sequencing confirmed that the methylation density well correlated with p15 mRNA expression (unpublished data). In order to classify the AML samples according to the p15 expression level, we assumed that mean values below 2 SEs of the control BM samples were low p15 expression levels, and the others were high expression levels. Mutations of the FLT3 gene were also examined as previously described. 6 The levels of p15 mRNA expression according to cytogenetic risk groups and FLT3 mutations are summarized in Table 1 . Of 40 patients with favorable cytogenetics, 26 (65%) showed low p15 expression. On the other hand, 34 of the 68 (50%) remaining patients with either intermediate, adverse or undetermined cytogenetics had low p15 expression (P ¼ 0.13). There was no appreciable difference between p15 expression levels and ITDs or D835 mutations in the FLT3 gene. The clinical outcome in 98 patients with AML who received intensive chemotherapy was examined according to the p15 expression level. Remaining 10 patients who received supportive therapy only or mild chemotherapy because of older age or poor clinical condition were excluded from this analysis. No statistical significance was observed between the p15 expression level and the complete remission rate in 98 AML patients.
Patients with favorable cytogenetics consisting of t(8;21), t(15;17) and inv(16), which were confirmed by RT-PCR analysis, showed significantly longer survival than those with intermediate or adverse cytogenetics according to the MRC criteria (P ¼ 0.039) (Figure 1a) . In univariate analysis, there were no significant differences between the p15 expression level and DFS, event-free survival (EFS), or overall survival (OS) (Figure 1b and data not shown). A total of 38 patients with favorable cytogenetics had no differences between the p15 expression level and DFS, EFS, or OS (P ¼ 0.82, 0.79, 0.95, respectively). Since 11 patients with undetermined cytogenetics were neither M2 with t(8;21), M3 with t(15;17), nor M4Eo with inv(16) by morphological and RT-PCR analyses, we included these patients in the intermediate or adverse cytogenetic risk group. Among the patients with intermediate or adverse cytogenetics, OS in patients with low p15 expression was significantly shorter than those with high p15 expression (P ¼ 0.027) (Figure 1c ). There were also significant differences between the p15 expression level and DFS (P ¼ 0.029) or EFS (P ¼ 0.028) in these patients (data not shown). In this study, the trend toward inferior clinical outcome in patients with FLT3-ITD did not reach statistical significance, possibly due to a small number of patients with FLT3-ITD (P ¼ 0.064). In addition, D835 mutation of the FLT3 gene had little influence on the survival, which was in line with the previous reports. When patients without FLT3-ITD were analyzed, high p15 expression was also associated with significantly longer DFS (P ¼ 0.041), EFS (P ¼ 0.018) and OS (P ¼ 0.014) in patients with intermediate or adverse cytogenetics (Figure 1d and data not shown) . A multivariate analysis revealed that low p15 expression was an independent unfavorable prognostic factor in predicting EFS in all 98 evaluable patients (P ¼ 0.042), in addition to a trend toward significance in DFS (P ¼ 0.12) and OS (P ¼ 0.075). In AML patients with intermediate or adverse cytogenetics, the multivariate analysis showed that low p15 expression was an independent unfavorable prognostic factor for predicting DFS (P ¼ 0.0050), EFS (P ¼ 0.015) and OS (P ¼ 0.014). ITD: internal tandem duplication, D835: missense mutation at the D835 in the FLT3 gene. In the present study, no significant difference was found in survival according to the p15 expression level among all evaluable AML patients. Although we found no difference in survival according to the p15 expression level in patients with favorable cytogenetics, low p15 expression significantly correlated to unfavorable clinical outcome among the remaining 60 patients with intermediate or adverse cytogenetics. We previously reported that p15 inactivation by deletion and methylation was highly associated with poor DFS in adult patients with precursor B-cell acute lymphoblastic leukemia. 7 Inactivation of the p15 gene would increase the risk of relapse by escaping the effect of TGF-b-mediated growth suppression, resulting in progression of cell growth and inhibition of apoptosis. 8 However, p15 inactivation is not thought to be a very powerful regulator of cell proliferation, and thus it may not influence the clinical outcome in patients with favorable cytogenetics who show a good response to treatment. On the other hand, patients with intermediate or adverse cytogenetics who show a poor response to treatment might be susceptible to the proliferative effect caused by p15 silencing. Our results suggest that low p15 expression detected by RQ-PCR could be a useful marker for prognosis in AML patients, especially in the intermediate or adverse cytogenetic risk group. The demethylating agent 5-AzadC has been shown to reverse the hypermethylation of the p15 gene in vitro and in vivo. We also showed 2-5-fold increases in p15 mRNA expression after 5-Aza-dC treatment in four of seven fresh leukemic cells from AML patients in vitro. This suggests that patients with low p15 expression may benefit from treatment with demethylating agents.
